

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS

llse Zolle, et al

SERIAL NO.

10/635,294

FILED

August 6, 2003

FOR

Radiolabelled Phenylethyl Imidazole Caboxylic Acid

Ester Derivatives

ART UNIT

To Be Assigned

EXAMINER

To Be Assigned

January 9, 2004

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

SIR:

Pursuant to 37 CFR §§ 1.56, 1.97 and 1.98, Applicants respectfully request that the Examiner consider the references listed on the attached Form PTO-1449.

This information disclosure statement is being filed within three months of the filing date of the application, or within three months of entry into the national stage, or before the mailing of a first Office Action on the merits. Pursuant to 37 CFR § 1.97(b), consideration of this information disclosure statement does not require a fee or a statement under 37 CFR § 1.97(e). However, should the Assistant Commissioner determine that a fee is, in fact, due, the Assistant Commissioner is hereby authorized to charge the fee to Deposit Account No. 14-1263.

Copies of all references listed on the attached Form PTO-1449 are being supplied.

Consideration of the foregoing in relation to this application is respectfully requested.

Respectfully submitted,

NORRIS MCLAUGHLIN & MARCUS, P.A.

Theodore A. Gottlieb

Reg. No. 42,597

220 East 42nd Street 30th Floor New York, New York 10017 (212) 808-0700

CERTIFICATE OF EXPRESS MAILING

I hereby certify that the foregoing Information Disclosure Statement and the accompanying Form PTO-1449 (1 Sheet) is being deposited with the United States Postal Service as express mail Express Mail Label No. <u>EV383033872 US</u> in an envelope addressed to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450, on the date indicated below:

Date: 1 9 04

By Agorta Chinsha

Agata Glinska

LIST OF PATENTS AND PUBLICATIONS Attorney Docket: 103218-1 Serial No.: 10/635,294 APPLICANT'S INFORMATION DISCLOSURE STATEMENT Applicant: Ilsa Zolle etal. (Form PTO-1449) Filing Date: August 6, 2003 Group: To Be Assigned **U.S. PATENT DOCUMENTS** Examiner **Document Number** Name Class Sub **Filing Date** Date RADER Class If appropriate FOREIGN PATENT DOCUMENTS Sub Translati n **Document Number** Date Country Class Class Yes N OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) Α Beierwaltes W. H., Wieland D. M., Ice R. D., Seabold J.E., Sarkar S. D., Gill S. P., and Mosley S. T.: Localization of radiolabeled enzyme inhibitors in the adrenal gland. J. Nucl. Med., 17(11), 998-1002, Napoli J.L., Counsel R.E.: New inhibitors of steroid 11\(\beta\)-hydroxylase. Structure-activity relationship В studies of metyrapone-like compounds. J. Med. Chem., 20, 762-766 (1997). C Beierwaltes W. H., Wieland D. M., Mosley S. T., Swanson D.P., Sarkar S.D, Freitas J.E., Thrall J.H. and Herwig K.R.: Imaging the adrenal glands with radiolabeled inhibitors of enzymes: concise communication. J. Nucl. Med., 19(2), 200-203, 1978. D Beierwaltes W.H., Wieland D.M., Yu T., Swanson D.P., Mosley S.T.: Adrenal Imaging Agents: Rationale, Synthesis, Formulation and, Metabolism. Semin. Nucl. Med., 8: No. 1: 5-21, 1978 E Robien W. And Zolle I. (1983) Synthesis of radioiodinated metyrapone-A potential agent for functional imaging of the adrenal cortex. Int. J. Appl. Radiat. Isot. 34: 907-914. F Zolle I., Woloszczuk W., and Hofer R.: Synthesis and in vitro evaluation of metyrapone derivatives as potential inhibitors of 11β-hydroxylase activity. In: Radiopharmaceuticals and labeled compounds, 337-342, IAEA-CN-45/67, Vienna, 1985. G Vanden Bossche H., Willemsens G., Cools W., Bellens D. (1984) Effects of etomidate on steroid biosynthesis in subcellular fractions of bovine adrenals. Biochemical Pharmacology: 33(23), 3861-3868 Η Engelhardt D (1994) Steroid biosynthesis inhibitors in Cushing's syndrome. Clin Investig 72: 481-488. I Wagner R.L., White P.F., Kan P.B., Rosenthal M.H., Feldman d. (1984) Inhibition of adrenal steroidogenesis by the anesthetic etomidate. New England J.Medicine: 310(22): 1415-1421. J Godefroi, E.F., Janssen, P.A.J., Van der Eycken, C.A.M., Van Heertum, A.H.M.T., Niemegeers, C.J.E. (1965) DL-1-(1-Arylalkyl)imidazole-5-caroxylate esters. A novel type of hypnotic agents. J. Med. Chem. 8: 220-223. K Yu, J., Zolle, I., Mertens, J., and Rakias, F.: Synthesis of 2-(131)-iodophenyl-metyrapone using Cu(I)assisted nucleophilic exchange lebelling: Study of the reaction conditions. Nucl. Med. & Biol. 22(2):257-262 (1995). L De Coster R., Degryse A.-D., Van Dijk P., Ooms L.A.A., Lagerweij E. (1987) Comparison of the effects

> of etomidate and its fluoro analogue, r 8110, on plasma cortisol, 11β-deoxycortisol, 17α-hydroxyprogesterone and testosterone concentrations in dogs. J. vet. Pharmacol. Therap. 10: 227-232

M

N

Berström M, Bonasera TA, Lu L, Bergström E, Backlin C, Juhlin C, Langström B (1998) In vitro and in

vivo primate evaluation of carbon-11- etomidate and carbon -11-metomidate as a potential traces for

Bergström M, Juhlin C, Bonasera TA, Sundin A, Rastad J, Akerström G, Langerström B, (2000) PET

imaging of adrenal cortical tumors with the 11b-hydroxylase tracer ¹¹ C- metomidate. J Nucl Med 41:

PET imaging of the adrenal cortex and its tumors. J Nucl Med 39: 982-989.

TPE O		275 202
	\	275-282.
JAN 0 9 2004	EEIGE	Khan T. S., Sundin A, Juhlin C., Langertröm B., Bergström M., Eriksson B. (2003) ¹¹ C- metomidate PET imaging of adrenocortical cancer. Eur. J. Med. & Molec. Imaging Vol. 30: 403-410
TO TRADEMENT	P	Reincke M, Fassnacht M, Väth S, Mora P, Allolio B (1996) Adrenal incidentalomas: A manifestation of the metabolic syndrome. Endocrine Research 22 (4): 757-761.
	Q	Herrera MF, Grant CS, van Heeerden JA, et al. (1991) Incidentally discovered adrenal tumors: an institutional perspective. Surgery 110: 1014-1021.
	R	Kloos RT, Gross MD, Francis IR, Korobkin M, Shapiro B, (1995) Incidentally discovered adrenal masses. Endocrin Rev. 16: 460-484.
	S	Mantero F., Terzolo M., Arnaldi G., Osella G., Masini A.M., Ali A., Giovagnetti M., Opocher G., Angeli A. (2000) A survey on adrenal incidentaloma in Italy. J. Endocrinol. & Metab. 85(2): 637-644
	Т	Mitsunobu O. (1981) Synthesis: 1-28.
		Hughes D. L. (1992) Org. Reactions 42: 335-656.
	U	Hughes D. L. (1996) Org Prep Proced. Int. 28: 127-164.
	v	Merkushev E. B. (1988) Synthesis: 923-937
	w	Ali H. and van Lier J. E. (1996) Synthesis: 423-445.
	х	Baldwin R.M., Zea-Ponce Y., Zoghbi S.S., Lauelle M., Al-Tikriti M.S., Sybirska E.H. Malison R.T., Neumeyer J.L., Milius R.A., Wang S., Stabin M., Smith E.O., Charney D.S., Hoffer P.B., and Innis RB (1993) Evaluation of the monoamine uptake site ligand [¹²³ I] methyl -3β-(4-iodophenyl)- tropane-2β-carboxylate([¹²³ I]β-CIT) in non-human primates: pharmacokinetics, biodistribution and SPECT brain imaging coregistered with MRI. Nucl. Med. Biol. 20: 597-606.
	Y	Laumen K. and Schneider M.P. (1988) J. Chem. Soc. Chem. Comm.: 598-600.
	Z	Botta M., Summa V., Trapassi G., Monteagudo E., Corelli F., (1994) Tetrahedron: Asymmetry 5: 181-184.
	AA	Corelli F., Summa V., Brogi A., Monteagudo E., Botta M., (1995) J. Org. Chem. 60: 2008-2015.
<u> </u>		
·	l	
EXAMINER:		DATE CONSIDERED:

EXAMINER: Initial if Reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformation and not considered, include copy of this form with next communication to applicant.